Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This trial combines trastuzumab and bevacizumab monoclonal antibodies, with ABI-007 and
carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers
demonstrating HER2 gene amplification. It is hoped that this novel combination will result in
increased pathologic response rates that will translate into long term outcome improvements
in HER2 positive patients with locally advanced breast cancer.